Israel Active

On 2nd Mar, the JNF is hosting a webinar featuring Israeli and US innovations in the Life Sciences. It includes the Chief Scientific & Medical Officer Prof. Dror Mevorach of Israel’s Enlivex Therapeutics - developer of COVID-19 “cure” Allocetra.  Registration required; donations are welcome.

Israel’s Gamida Cell (reported previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the hospital.

Researchers at Israel’s Weizmann Institute have overcome the resistance of the most aggressive forms of multiple myeloma. In a trial of 41 patients at 15 Israeli hospitals they discovered that Cyclosporin A neutralizes the disease’s resistance to cancer-killing proteasome inhibitors.

Israel’s PM heralded the latest Israeli Covid-19 therapy, EXO-CD24, developed at Tel Aviv’s Sourasky (Ichilov) Medical Center. When given to 30 moderate to severe Covid-19 patients, 29 were discharged 3-5 days after having the treatment and one recovered a little later.

Hebrew University scientists have developed a blood test that they say could replace nearly all cancer screenings within a decade. It detects cancer cells and identifies the exact location of the tumor in the body. New Israeli startup Senseera will now perform clinical trials.

Israel’s AIVF has devised a method to test embryos in vitro in a noninvasive manner to detect possible genetic abnormalities. Its scanning device and an AI algorithm avoids the current riskier PGT (Preimplantation Genetic Testing) biopsies which remove cells from the embryo.

Professor Moshe Phillip of Israel’s Schneider Children's hospital was awarded the Andrea Prader Lifetime Achievement Prize by the European Society of Pediatric Endocrinology (ESPE) for his outstanding contribution towards pediatric endocrinology.

Patients often lapse their health improvement programs. Israel’s Well-Beat (reported previously) recently completed a pilot at Sheba’s Cardiac Rehabilitation Center where it proved to triple adherence to recommended care. Well-Beat recently received its 3rd Israel Innovation Authority grant.

Hebrew University of Jerusalem researchers and Seattle scientists have demonstrated the restoration of communication between damaged nerve cells. They implanted artificial connections (synapses) in the nervous systems of tiny translucent C. elegans worms.

Israel’s Ukko is working to re-design gluten proteins so that they do not trigger an immune response in people with celiac and other gluten sensitivities. In addition, Ukko is developing an edible medicine that can promote immune tolerance for people with peanut allergy.